A valuable academic-style experience with limited industry transition opportunities - Postdoctoral Researcher bei Merck: Mitarbeiterbewertung

3,0
19. Apr. 2025
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Offers an excellent environment for those seeking to strengthen their research credentials. The role provides access to cutting-edge resources, expert guidances, and strong supports from mentors and peers. Regular group meetings, opportunities, to present at conferences, and clear publication expectations make it an ideal setup for anyone aiming to build a strong scientific portfolio.

Kontras

From a career development perspective, the role has some limitations- especially for those aiming for long-term industry placement. The projects are often highly specialized and can be quite isolating, sometimes with limited overlap or alignment with the broader team focus. This can restrict exposure to cross-functional or pipeline-related experiences that are essential for many full-time industry roles. Another important consideration is the low conversion rate to permanent positions, with fewer than ~30% of the postdocs being converted into full-time roles. While they invest significant time and training into postdocs, there is no guaranteed path to transition- which is something prospective candidates should weigh carefully.

Mehr Bewertungen zu Merck entdecken

5,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Excellent company to work with.

Kontras

No cons encountered so far

4,0
30. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Kontras

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle